Page 1

Numinus Wellness Inc. Announces Fourth Quarter Fiscal 2025 Results and Provides Corporate Update August 28 , 2026 Q4 Fiscal 2025 Highlights • Revenue of $ 2.3 million , a 29.0 % increase over Q3 2025 • Gross profit of $ 1.4 million , compared to a gross profit of $ 0.8 million in Q3 2025 • Cash position of $ 0.5 million as of August 31 , 2025 Subsequent to Quarter End • On April 18 , 2026 , President Donald Trump signed an executive order directing U.S. federal agencies to accelerate research , access , and regulatory review for psychedelic - based treatments , including psilocybin , ibogaine , MDMA , and LSD , and committing US $ 50 million in federal support for state - level programs . The Company views this as a meaningful regulatory development for its clinical research operations and practitioner training programs , both of which are actively engaged in psychedelic research delivery and practitioner readiness . The ultimate impact , however , will depend on further agency implementation by the FDA and DEA . All financial results are reported in Canadian dollars unless otherwise stated . Vancouver , British Columbia -- ( Newsfile Corp. - August 28 , 2026 ) - Numinus Wellness Inc. ( OTC Pink : NUMIF ) ( " Numinus " or the " Company " ) a mental health care company focused on innovative behavioral health treatments with a focus on safe , evidence - based psychedelic - assisted therapies , today announced its financial results for the three months and year ended August 31 , 2025 ( " Q4 2025 " ) . Revenue from continuing operations The Company's consolidated revenues increased by 29.0 % quarter over quarter compared to Q3 2025 . Revenues from Cedar Clinical Research ( " CCR " ) operations during Q4 2025 decreased by 13.2 % from $ 1.6 million during Q3 2025 to $ 1.4 million as a result of seasonality impacts relating to clinical trial patients . Revenues from Practitioner Training during Q4 2025 increased by 387.6 % from $ 0.2 million during Q3 2025 to $ 1.0 million . The increase in revenue was due to the ramp up of strategic contracts with a research partner to help support the training efforts of various psychedelic clinical trials . Gross Margin Gross margin in Q4 2025 was 61.2 % , compared to a gross profit of 48.3 % in Q3 2025 . Operating expenditures Operating expenditures and other items were $ 2.9 million in Q4 2025 , compared to $ 1.7 million in the previous quarter . The increase is a result of the Company's ongoing cost containment initiatives and operational optimization . Operational Highlights Numinus Clinical Research Revenues from CCR during Q4 2025 were $ 1.4 million , a decrease of 13.2 % compared to Q3 2025 . CCR managed 18 clinical trials , including 306 patient appointments in Q4 2025 , compared to 15 clinical trials and 233 patient appointments in Q3 2025 . Practitioner Training